Calando Pharmaceuticals.

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors Arrowhead Research Company today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc. It is thought to be the 1st ever demonstration in human beings of targeted siRNA-made up of nanoparticle delivery to tumors using systemic administration, delivery of practical siRNAs, and achievement of specific proteins and mRNA reductions via RNAi. Significantly in the trial Thus, no significant drug-related toxicities, known as serious adverse occasions , have been observed that may limit make use of gastrointestinal spasm .